| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.063 | 0.2 |
| mRNA | isoliquiritigenin | CTRPv2 | pan-cancer | AAC | -0.076 | 0.2 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.3 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |